Navigation Links
Ambit Biosciences Announces Third Quarter 2013 Operating Results
Date:11/7/2013

$3.1 million and $1.2 million for the quarters ended September 30, 2013 and 2012, respectively.  The increase of $1.8 million was primarily due to increased costs related to patent prosecution, personnel-related expenses, stock-based compensation expense and consulting for market research, organizational development and planning related to the return of full rights for quizartinib.

Other expenses (net) were $8.7 million and $2.0 million for the three months ended September 30, 2013 and 2012, respectively.  The increase of $6.7 million was primarily due to the change in fair value of the Company's stock warrant liabilities, which is driven by the change in fair value of the underlying preferred or common securities.

Year-To-Date Results
Revenues were $25.8 million and $14.7 million for the nine months ended September 30, 2013 and 2012, respectively.  The increase of $11.1 million was primarily due to acceleration in the recognition of license fee revenue related to the Company's collaboration with Astellas Pharma.  In March 2013, the Company received a notice of termination of the agreement from Astellas, which termination was effective September 2013. 

Research and development expenses were $20.2 million and $30.1 million for the nine months ended September 30, 2013 and 2012, respectively.  The decrease of $10.0 million was primarily due to lower quizartinib research and development expenses.  This resulted from a reduction in the number of patients being treated and followed in our Phase 2 clinical trial, for which enrollment of patients was completed in late 2011. 

General and administrative expenses were $7.0 million and $4.5 million for the nine months ended September 30, 2013 and 2012, respectively.  The increase of $2.5 million was primarily due to increased costs related to patent prosecution, stock-based compensation expense, personnel-related expenses and consulting for market res
'/>"/>

SOURCE Ambit Biosciences
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Ambit Announces Participation At 12th Annual BIO Investor Forum
2. Ambit Announces Participation At The BioCentury NewsMakers in the Biotech Industry Conference
3. Ambit Announces Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the Annual Meeting of the American Society of Clinical Oncology
4. Ambit Biosciences Files Registration Statement for Proposed Initial Public Offering
5. APAC Stem Cell Research & Therapy Market a “Growth Engine” for Region’s Scientific Ambitions Says A New Market Research Report at ReportsnReports.com
6. Astellas and Ambit Announce Data Presentations Highlighting Quizartinib at the American Society of Hematology 54th Annual Meeting
7. Ambit Biosciences to Present at Two Upcoming Investor Conferences
8. Ambit and Astellas Announce Results From Multiple Quizartinib Presentations at the 53rd Annual Meeting of the American Hematology Society
9. Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
10. Pressure BioSciences, Inc. Reports Third Quarter 2013 Financial Results and Provides Business Update
11. Juneau Biosciences Names Dr. Dinesh Patel to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... Irvine, CA (PRWEB) March 04, 2015 ... research leader in Personalized Medicine, is excited to ... “Incorporating Genetic Testing to Optimize the Management of ... be available at Medscape.com for the next year. ... medical professionals how to recognize inadequate pain treatments, ...
(Date:3/4/2015)... San Jose, California (PRWEB) March 04, 2015 ... Chain Reaction (PCR) represents one of the fastest growing ... among cell biologists in subcellular visualization is driving growth ... The need for deeper understanding of gene expressions will ... reagents market. Expanding applications in fields ranging from pharma, ...
(Date:3/3/2015)... March 3, 2015 /PRNewswire/ - Aptose Biosciences Inc. (NASDAQ: ... and molecular diagnostics that target the underlying mechanisms of ... seventh-month period ended December 31, 2014. Effective ... end from May 31 to December 31. As a ... today are for the quarter and the seven months ...
(Date:3/3/2015)... Inc. (TSXV: BRM) ("Biorem" or "the Company") today announced several new ... in North America , the Middle ... "Bidding activity in 2015 continues to be robust" said Derek ... for bidding in 2014, we are pleased to see the bidding ... organization,s renewed focus on select market segments where we can add ...
Breaking Biology Technology:Proove Biosciences Launches CME Accredited Program with Medscape 2Proove Biosciences Launches CME Accredited Program with Medscape 3Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 2Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 3Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 4Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 2Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 3Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 4Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 5Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 6Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 7Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 8Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 9Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 10Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 11Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 12
... HOLX ), a diversified medical technologies company ... dedicated to,serving the healthcare needs of women, today ... operating results on Thursday, May 1, 2008 at,8:00 ... will host,a conference call on Thursday, May 1, ...
... Wednesday, May 7, 2008 TIME: ... HOST: ... conduct a telephone conference call and,simultaneous webcast on Wednesday, May 7 at 9:30 ... 31, 2008. A,question and answer session will follow., Webcast Instructions, To ...
... by Mid-2008, COLLEGEVILLE, Pa. and TARRYTOWN, ... division of Wyeth (NYSE: WYE ), ... today announced that the companies,have received a ... from the Committee for Medicinal Products,for Human ...
Cached Biology Technology:Hologic, Inc. to Release Second Quarter Fiscal 2008 Operating Results Thursday, May 1st Before Market Opens 2Kendle Invites You to Attend its First Quarter 2008 Earnings Conference Call and Webcast 2Wyeth and Progenics Receive Positive Opinion From European Committee for RELISTOR for the Treatment of Opioid-Induced Constipation in Advanced-Illness Patients 2Wyeth and Progenics Receive Positive Opinion From European Committee for RELISTOR for the Treatment of Opioid-Induced Constipation in Advanced-Illness Patients 3Wyeth and Progenics Receive Positive Opinion From European Committee for RELISTOR for the Treatment of Opioid-Induced Constipation in Advanced-Illness Patients 4Wyeth and Progenics Receive Positive Opinion From European Committee for RELISTOR for the Treatment of Opioid-Induced Constipation in Advanced-Illness Patients 5
(Date:2/5/2015)... 26, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... authentication company focused on the growing mobile commerce market, ... http://www.nxt-id.com/ ) as part of its 2015 marketing and ... launched its new consumer website for Wocketwallet.com earlier this ... of NXT-ID said, "Our new corporate website naturally showcases ...
(Date:2/5/2015)... FRANCISCO , January 28, 2015 ... Market Analysis, Size And Segment Forecasts To 2020 has ... global IR camera market is expected to reach USD ... by Grand View Research, Inc. IR cameras help identify ... and are expected to witness surging demand in medical ...
(Date:2/5/2015)... DUBLIN , Jan. 28, 2015 Research ... announced the addition of the "Global Biometrics ... Use, Regions and Countries " report to their ... market, Asia-Pacific is anticipated ... by 2015, owing to increasing government spending towards ...
Breaking Biology News(10 mins):NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 2NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 3IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 3Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 2Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 3
... hypoxia in Green Bay, part of Lake Michigan, Wisc., have ... four-year $1,367,300 project through NOAA,s Coastal Hypoxia Research Program. Hypoxia ... recent evidence suggests that it may be worsening, with the ... more frequent and more extensive with a changing climate. ...
... Edinburgh, shows that sugary drinks, consumed in moderate quantities, ... mood effects in overweight women when they do not ... ,Effects of sucrose drinks on macronutrient intake, body weight, ... which was conducted by Marie Reid, Richard Hammersley and ...
... RICHLAND, Wash. -- As much as 12 percent of the ... producing biochar, a charcoal-like substance made from plants and other ... the same plants and materials were burned to generate energy, ... Communications ., These calculations show that biochar can play a ...
Cached Biology News:NOAA awards grant to investigate impacts of land use and climate change on hypoxia in Green Bay 2Research shows sugary drinks do not cause weight gain 2Charcoal takes some heat off global warming 2Charcoal takes some heat off global warming 3Charcoal takes some heat off global warming 4Charcoal takes some heat off global warming 5
... were designed for full-length gene cloning and ... identify the desired cDNA clone. The first ... "Master Plate," where each well contains plasmid ... positive well(s) by gel electrophoresis of the ...
... CEQ 8800 Genetic Analysis System, which processes ... This automated system adds a higher level of ... CEQ 8800, part of Beckman Coulters new GenomeLab ... link with the Biomek series liquid handers, for ...
... cDNA Library Panels were designed for full-length ... of PCRs to identify the desired cDNA ... in a 96-well "Master Plate," where each ... Having identified the positive well(s) by gel ...
... cDNA Library Panels were designed for full-length ... of PCRs to identify the desired cDNA ... in a 96-well "Master Plate," where each ... Having identified the positive well(s) by gel ...
Biology Products: